LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 464

Search options

  1. Book: How to incorporate a chemo-free interval into the management of metastatic colorectal cancer

    Grothey, Axel / Ciardiello, Fortunato / Marshall, John L.

    (Clinical advances in hematology & oncology : Clinical roundtable monograph ; volume 18, issue 10, supplement 16 (October 2020))

    2020  

    Author's details moderator Axel Grothey, MD ; discussants Fortunato Ciardiello, MD, PhD, John L. Marshall, MD
    Series title Clinical advances in hematology & oncology : Clinical roundtable monograph ; volume 18, issue 10, supplement 16 (October 2020)
    Clinical advances in hematology & oncology
    Clinical advances in hematology & oncology
    Collection Clinical advances in hematology & oncology
    Clinical advances in hematology & oncology
    Language English
    Size 23 Seiten, Diagramme
    Publisher Millennium Medical Publishing
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT020674839
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6505 -18,Suppl.16- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Why chemo-free treatment intervals can improve care of patients with metastatic colorectal cancer.

    Ciardiello, Fortunato

    Clinical advances in hematology & oncology : H&O

    2021  Volume 18 Suppl 16, Issue 10, Page(s) 3–5

    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols ; Colorectal Neoplasms/therapy ; Disease-Free Survival ; Humans ; Neoplasm Metastasis
    Language English
    Publishing date 2021-04-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Angiogenesis inhibition in metastatic colorectal cancer continuum of care.

    Martinelli, Erika / Ciardiello, Fortunato

    Lancet (London, England)

    2023  Volume 402, Issue 10395, Page(s) 4–5

    MeSH term(s) Humans ; Bevacizumab/therapeutic use ; Angiogenesis Inhibitors/therapeutic use ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Continuity of Patient Care ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/pathology
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; Angiogenesis Inhibitors
    Language English
    Publishing date 2023-06-15
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(23)00867-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 94: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Targeting the EGFR signalling pathway in metastatic colorectal cancer.

    Napolitano, Stefania / Martini, Giulia / Ciardiello, Davide / Del Tufo, Sara / Martinelli, Erika / Troiani, Teresa / Ciardiello, Fortunato

    The lancet. Gastroenterology & hepatology

    2024  

    Abstract: Epidermal growth factor receptor (EGFR) and its activated downstream signalling pathways play a crucial role in colorectal cancer development and progression. After four decades of preclinical, translational, and clinical research, it has been shown that ...

    Abstract Epidermal growth factor receptor (EGFR) and its activated downstream signalling pathways play a crucial role in colorectal cancer development and progression. After four decades of preclinical, translational, and clinical research, it has been shown that blocking the EGFR signalling pathway at different molecular levels represents a fundamental therapeutic strategy for patients with metastatic colorectal cancer. Nevertheless, the efficacy of molecularly targeted therapies is inescapably limited by the insurgence of mechanisms of acquired cancer cell resistance. Thus, in the era of precision medicine, a deeper understanding of the complex molecular landscape of metastatic colorectal cancer is required to deliver the best treatment choices to all patients. Major efforts are currently ongoing to improve patient selection, improve the efficacy of available treatments targeting the EGFR pathway, and develop novel combination strategies to overcome therapy resistance within the continuum of care of metastatic colorectal cancer.
    Language English
    Publishing date 2024-04-29
    Publishing country Netherlands
    Document type Journal Article ; Review
    ISSN 2468-1253
    ISSN (online) 2468-1253
    DOI 10.1016/S2468-1253(23)00479-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Maintenance therapy for metastatic colorectal cancer.

    Ciardiello, Fortunato

    The Lancet. Oncology

    2015  Volume 16, Issue 15, Page(s) 1444–1445

    MeSH term(s) Angiogenesis Inhibitors/administration & dosage ; Antineoplastic Agents/administration & dosage ; Bevacizumab/administration & dosage ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/secondary ; Erlotinib Hydrochloride/administration & dosage ; Female ; Humans ; Maintenance Chemotherapy ; Male
    Chemical Substances Angiogenesis Inhibitors ; Antineoplastic Agents ; Bevacizumab (2S9ZZM9Q9V) ; Erlotinib Hydrochloride (DA87705X9K)
    Language English
    Publishing date 2015-11
    Publishing country England
    Document type Comment ; Journal Article
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(15)00308-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Towards the era of precision medicine in metastatic colorectal cancer.

    Napolitano, Stefania / Troiani, Teresa / Martinelli, Erika / Ciardiello, Fortunato

    ESMO open

    2020  Volume 5, Issue 2

    MeSH term(s) Colorectal Neoplasms/epidemiology ; Humans ; Neoplasm Metastasis ; Precision Medicine/methods
    Language English
    Publishing date 2020-03-27
    Publishing country England
    Document type Editorial
    ISSN 2059-7029
    ISSN (online) 2059-7029
    DOI 10.1136/esmoopen-2020-000685
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Clinical management of metastatic colorectal cancer in the era of precision medicine.

    Ciardiello, Fortunato / Ciardiello, Davide / Martini, Giulia / Napolitano, Stefania / Tabernero, Josep / Cervantes, Andres

    CA: a cancer journal for clinicians

    2022  Volume 72, Issue 4, Page(s) 372–401

    Abstract: Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in approximately 20% of patients. Moreover, up to 50% of patients with ...

    Abstract Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in approximately 20% of patients. Moreover, up to 50% of patients with localized disease eventually develop metastases. Appropriate clinical management of these patients is still a challenging medical issue. Major efforts have been made to unveil the molecular landscape of mCRC. This has resulted in the identification of several druggable tumor molecular targets with the aim of developing personalized treatments for each patient. This review summarizes the improvements in the clinical management of patients with mCRC in the emerging era of precision medicine. In fact, molecular stratification, on which the current treatment algorithm for mCRC is based, although it does not completely represent the complexity of this disease, has been the first significant step toward clinically informative genetic profiling for implementing more effective therapeutic approaches. This has resulted in a clinically relevant increase in mCRC disease control and patient survival. The next steps in the clinical management of mCRC will be to integrate the comprehensive knowledge of tumor gene alterations, of tumor and microenvironment gene and protein expression profiling, of host immune competence as well as the application of the resulting dynamic changes to a precision medicine-based continuum of care for each patient. This approach could result in the identification of individual prognostic and predictive parameters, which could help the clinician in choosing the most appropriate therapeutic program(s) throughout the entire disease journey for each patient with mCRC. CA Cancer J Clin. 2022;72:000-000.
    MeSH term(s) Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Colonic Neoplasms ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/therapy ; Humans ; Precision Medicine ; Prognosis ; Rectal Neoplasms ; Tumor Microenvironment
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2022-04-26
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 603553-x
    ISSN 1542-4863 ; 0007-9235
    ISSN (online) 1542-4863
    ISSN 0007-9235
    DOI 10.3322/caac.21728
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 100: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer.

    Caputo, Vincenza / Ciardiello, Fortunato / Corte, Carminia Maria Della / Martini, Giulia / Troiani, Teresa / Napolitano, Stefania

    Exploration of targeted anti-tumor therapy

    2023  Volume 4, Issue 1, Page(s) 102–138

    Abstract: Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring oncological decision-making. It analyzes different blood-circulating ... ...

    Abstract Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring oncological decision-making. It analyzes different blood-circulating biomarkers and circulating tumor DNA (ctDNA) is the preferred one. Nevertheless, tissue biopsy remains the gold standard for molecular evaluation of solid tumors whereas liquid biopsy is a complementary tool in many different clinical settings, such as treatment selection, monitoring treatment response, cancer clonal evolution, prognostic evaluation, as well as the detection of early disease and minimal residual disease (MRD). A wide number of technologies have been developed with the aim of increasing their sensitivity and specificity with acceptable costs. Moreover, several preclinical and clinical studies have been conducted to better understand liquid biopsy clinical utility. Anyway, several issues are still a limitation of its use such as false positive and negative results, results interpretation, and standardization of the panel tests. Although there has been rapid development of the research in these fields and recent advances in the clinical setting, many clinical trials and studies are still needed to make liquid biopsy an instrument of clinical routine. This review provides an overview of the current and future clinical applications and opening questions of liquid biopsy in different oncological settings, with particular attention to ctDNA liquid biopsy.
    Language English
    Publishing date 2023-02-28
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2692-3114
    ISSN (online) 2692-3114
    DOI 10.37349/etat.2023.00125
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer.

    Ciardiello, Fortunato / Hirsch, Fred R / Pirker, Robert / Felip, Enriqueta / Valencia, Christian / Smit, Egbert F

    Cancer treatment reviews

    2023  Volume 122, Page(s) 102664

    Abstract: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the current recommended option for the first-line treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). Resistance to first-generation TKIs led to the ... ...

    Abstract Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the current recommended option for the first-line treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). Resistance to first-generation TKIs led to the development of second- and third-generation TKIs with improved clinical outcomes. However, sequential administration of TKIs has led to the emergence of new EGFR resistance mutations and persistent tumor cell survival. This evidence highlights the potential role of EGFR in transducing growth signals in NSCLC tumor cells. Therefore, dual inhibition of EGFR using combinations of anti-EGFR monoclonal antibodies (mAbs) and EGFR-TKIs may offer a unique treatment strategy to suppress tumor cell growth. Several clinical studies have demonstrated the benefits of dual blockade of EGFR using anti-EGFR mAbs coupled with EGFR-TKIs in overcoming treatment resistance in patients with EGFR-mutated NSCLC. However, a single treatment option may not result in the same clinical benefits in all patients with acquired resistance. Biomarkers, including EGFR overexpression, EGFR gene copy number, EGFR and KRAS mutations, and circulating tumor DNA, have been associated with improved clinical efficacy with anti-EGFR mAbs in patients with NSCLC and acquired resistance. Further investigation of biomarkers may allow patient selection for those who could benefit from anti-EGFR mAbs in combination with EGFR-TKIs. This review summarizes findings of recent studies of anti-EGFR mAbs in combination with EGFR-TKIs for the treatment of patients with EGFR-mutated NSCLC, as well as clinical evidence for potential biomarkers towards personalized targeted medicine.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; ErbB Receptors ; Protein Kinase Inhibitors/adverse effects ; Antineoplastic Agents/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal/pharmacology ; Mutation ; Biomarkers ; Drug Resistance, Neoplasm
    Chemical Substances ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors ; Antineoplastic Agents ; Antibodies, Monoclonal ; Biomarkers ; EGFR protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2023-11-25
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 125102-8
    ISSN 1532-1967 ; 0305-7372
    ISSN (online) 1532-1967
    ISSN 0305-7372
    DOI 10.1016/j.ctrv.2023.102664
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1022: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 611: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC.

    De Rosa, Caterina / De Rosa, Viviana / Tuccillo, Concetta / Tirino, Virginia / Amato, Luisa / Papaccio, Federica / Ciardiello, Davide / Napolitano, Stefania / Martini, Giulia / Ciardiello, Fortunato / Morgillo, Floriana / Iommelli, Francesca / Della Corte, Carminia Maria

    Scientific reports

    2024  Volume 14, Issue 1, Page(s) 500

    Abstract: Osimertinib is a third-generation tyrosine kinase inhibitor clinically approved for first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC) patients. Although an impressive drug response is initially observed, in most of tumors, resistance ...

    Abstract Osimertinib is a third-generation tyrosine kinase inhibitor clinically approved for first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC) patients. Although an impressive drug response is initially observed, in most of tumors, resistance occurs after different time and an alternative therapeutic strategy to induce regression disease is currently lacking. The hyperactivation of MEK/MAPKs, is one the most common event identified in osimertinib-resistant (OR) NSCLC cells. However, in response to selective drug pressure, the occurrence of multiple mechanisms of resistance may contribute to treatment failure. In particular, the epithelial-to-mesenchymal transition (EMT) and the impaired DNA damage repair (DDR) pathways are recognized as additional cause of resistance in NSCLC thus promoting tumor progression. Here we showed that concurrent upregulation of ITGB1 and DDR family proteins may be associated with an increase of EMT pathways and linked to both osimertinib and MEK inhibitor resistance to cell death. Furthermore, this study demonstrated the existence of an interplay between ITGB1 and DDR and highlighted, for the first time, that combined treatment of MEK inhibitor with DDRi may be relevant to downregulate ITGB1 levels and increase cell death in OR NSCLC cells.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; ErbB Receptors/metabolism ; Drug Resistance, Neoplasm/genetics ; Mutation ; Aniline Compounds/pharmacology ; Aniline Compounds/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Mitogen-Activated Protein Kinase Kinases/genetics ; Cell Line, Tumor
    Chemical Substances osimertinib (3C06JJ0Z2O) ; ErbB Receptors (EC 2.7.10.1) ; Aniline Compounds ; Protein Kinase Inhibitors ; Mitogen-Activated Protein Kinase Kinases (EC 2.7.12.2) ; EGFR protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2024-01-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-023-50568-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top